减肥药降价50%、收购新管线，诺和诺德试图挽回投资者信心

Core Viewpoint - Novo Nordisk's stock has dropped over 20% this week due to the underperformance of its new weight loss drug CagriSema compared to Eli Lilly's tirzepatide [1] Group 1: Drug Development and Collaborations - Novo Nordisk announced a collaboration with Vivtex to develop next-generation oral medications for obesity and diabetes, with potential payments totaling up to $2.1 billion [1] - The partnership aims to combine Novo Nordisk's expertise in peptide and protein drugs with Vivtex's proprietary gastrointestinal screening and formulation platform to create oral delivery options for biologics [1] - Novo Nordisk also reported successful Phase II clinical trial results for UBT251, a GLP-1/GIP/GCG triple-target drug, in overweight/obese patients in China [1] Group 2: Pricing Strategy and Market Competition - Starting January 1, 2027, Novo Nordisk will significantly reduce the official wholesale prices of its semaglutide drugs in the U.S., with a 50% reduction for the weight loss version Wegovy and approximately 35% for the diabetes version Ozempic [2] - The price reduction aims to improve drug accessibility for more patients, particularly those with high out-of-pocket costs and high-deductible insurance plans [3] - Novo Nordisk faces competition from Eli Lilly's tirzepatide, which generated $36.507 billion in sales in 2025, surpassing Novo Nordisk's semaglutide sales of $36.1 billion [3] Group 3: Patent Expiry and Future Strategies - Novo Nordisk is preparing for the patent expiry of semaglutide in March 2026 in several markets, which will expose it to generic competition [3] - The company is responding by launching oral GLP-1 weight loss medication Wegovy tablets, which were approved in December 2022, and continuing to develop new therapies like CagriSema and UBT251 [3] - Analysts predict that investor focus may shift towards the company's acquisition strategy, with expectations that Novo Nordisk could spend up to $35 billion on acquisitions this year [4]